BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

861 related articles for article (PubMed ID: 18451260)

  • 1. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.
    Holland WL; Summers SA
    Endocr Rev; 2008 Jun; 29(4):381-402. PubMed ID: 18451260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceramides - Lipotoxic Inducers of Metabolic Disorders.
    Chaurasia B; Summers SA
    Trends Endocrinol Metab; 2015 Oct; 26(10):538-550. PubMed ID: 26412155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sphingolipids: players in the pathology of metabolic disease.
    Cowart LA
    Trends Endocrinol Metab; 2009 Jan; 20(1):34-42. PubMed ID: 19008117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sphingolipids and Lipoproteins in Health and Metabolic Disorders.
    Iqbal J; Walsh MT; Hammad SM; Hussain MM
    Trends Endocrinol Metab; 2017 Jul; 28(7):506-518. PubMed ID: 28462811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingolipids: agents provocateurs in the pathogenesis of insulin resistance.
    Lipina C; Hundal HS
    Diabetologia; 2011 Jul; 54(7):1596-607. PubMed ID: 21468641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance.
    Holland WL; Brozinick JT; Wang LP; Hawkins ED; Sargent KM; Liu Y; Narra K; Hoehn KL; Knotts TA; Siesky A; Nelson DH; Karathanasis SK; Fontenot GK; Birnbaum MJ; Summers SA
    Cell Metab; 2007 Mar; 5(3):167-79. PubMed ID: 17339025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingolipids and insulin resistance: the five Ws.
    Summers SA
    Curr Opin Lipidol; 2010 Apr; 21(2):128-35. PubMed ID: 20216312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A ceramide-centric view of insulin resistance.
    Chavez JA; Summers SA
    Cell Metab; 2012 May; 15(5):585-94. PubMed ID: 22560211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sphingolipids in obesity and related complications.
    Boini KM; Xia M; Koka S; Gehr TW; Li PL
    Front Biosci (Landmark Ed); 2017 Jan; 22(1):96-116. PubMed ID: 27814604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sphingolipids in metabolic disease: The good, the bad, and the unknown.
    Green CD; Maceyka M; Cowart LA; Spiegel S
    Cell Metab; 2021 Jul; 33(7):1293-1306. PubMed ID: 34233172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sphingolipids in High Fat Diet and Obesity-Related Diseases.
    Choi S; Snider AJ
    Mediators Inflamm; 2015; 2015():520618. PubMed ID: 26648664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sphingolipid synthetic pathways are major regulators of lipid homeostasis.
    Worgall TS
    Adv Exp Med Biol; 2011; 721():139-48. PubMed ID: 21910087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingolipids: major regulators of lipid metabolism.
    Worgall TS
    Curr Opin Clin Nutr Metab Care; 2007 Mar; 10(2):149-55. PubMed ID: 17285002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CerS6-Derived Sphingolipids Interact with Mff and Promote Mitochondrial Fragmentation in Obesity.
    Hammerschmidt P; Ostkotte D; Nolte H; Gerl MJ; Jais A; Brunner HL; Sprenger HG; Awazawa M; Nicholls HT; Turpin-Nolan SM; Langer T; Krüger M; Brügger B; Brüning JC
    Cell; 2019 May; 177(6):1536-1552.e23. PubMed ID: 31150623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sphingolipid metabolism and analysis in metabolic disease.
    Brice SE; Cowart LA
    Adv Exp Med Biol; 2011; 721():1-17. PubMed ID: 21910079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting sphingolipid metabolism in the treatment of obesity/type 2 diabetes.
    Bellini L; Campana M; Mahfouz R; Carlier A; Véret J; Magnan C; Hajduch E; Le Stunff H
    Expert Opin Ther Targets; 2015; 19(8):1037-50. PubMed ID: 25814122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingolipids and phospholipids in insulin resistance and related metabolic disorders.
    Meikle PJ; Summers SA
    Nat Rev Endocrinol; 2017 Feb; 13(2):79-91. PubMed ID: 27767036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceramides in Metabolism: Key Lipotoxic Players.
    Chaurasia B; Summers SA
    Annu Rev Physiol; 2021 Feb; 83():303-330. PubMed ID: 33158378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceramides in insulin resistance and lipotoxicity.
    Summers SA
    Prog Lipid Res; 2006 Jan; 45(1):42-72. PubMed ID: 16445986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sphingolipids in obesity, type 2 diabetes, and metabolic disease.
    Russo SB; Ross JS; Cowart LA
    Handb Exp Pharmacol; 2013; (216):373-401. PubMed ID: 23563667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.